CD274 and neoplasm: PD‐1 and PD‐L1 expressions in primary ccRCC have been reported to be associated with poor patient outcome and pathologic features associated with aggressive tumors.5, 6, 7 From a therapeutic standpoint, expression of these biomarkers in the primary tumor does not represent the most relevant evaluation.